ADCIRCA®, REMODULIN® AND TYVASO®

United Therapeutics

 
United Therapeutics created these programs to provide access to Remodulin®, Tyvaso® or Adcirca® and any related supplies for patients who cannot afford therapy because of their financial situations, those who do not have enough insurance or are between insurance plans, and those who have insurance restrictions.

Programs

Bridge Program provides medications to patients who are unable to access their treatment either because they are temporarily uninsured or going through a plan exclusion period.

Indigent Program provides access to medications to patients who do not have enough resources to pay for treatment and fall below 300% of the Federal Poverty Level.

Lifetime Cap Program provides access to medication to patients who are within $300,000 of reaching their insurance plan’s lifetime cap and make less than $25,000 per month.

Who is Eligible?

Bridge Program

You are eligible if you meet one of the following criteria:

  • Have changed jobs or stopped working and have COBRA or HIPPAA coverage
  • Have insurance with an exclusion period

and also meet all of the following criteria:

  • Less than $25,000 gross household income per month ($300,000 per year)
  • Take the medication for a FDA-approved diagnosis
  • Reside in the United States 
  • Be under the direct care of a licensed U.S. physician
  • Receive healthcare services via the U.S. healthcare system
  • Do not have federal healthcare or Massachusetts state coverage

    Indigent Program

    You are eligible if you meet one of the following criteria:

    • Insufficient financial resources to pay for treatment
    • Income is not more than 300% Federal Poverty Level and patient has documented proof that they do not have insurance coverage
    • A written denial from a state Medicaid program

    and also meet all of the following criteria:

    • Take the medication for a FDA-approved diagnosis
    • Reside in the United State
    • Be under the direct care of a licensed U.S. physician
    • Receive healthcare services via the U.S. healthcare system
    • Do not have federal healthcare or Massachusetts state coverage

    Lifetime Cap Program

    You are eligible if you meet the following criteria:

    • Less than $25,000 gross household income per month ($300,000 per year)
    • Be covered exclusively by an insurance policy with a lifetime cap
    • Be within $300,000 of reaching your lifetime cap (insurer must provide written statement)
    • Take the medication for a FDA-approved diagnosis
    • Reside in the United States
    • Be under the direct care of a licensed U.S. physician
    • Receive healthcare services via the U.S. healthcare system
    • Do not have federal healthcare or Massachusetts state coverage

    How Does The Program Work?

    All United Therapeutics’ Patient Assistance Programs are administered by one of its Distribution Partners, also known as Specialty Pharmacy Service Providers. Representatives from these companies are available to help guide you through the application process.

    For Remodulin® and Tyvaso®

    Contact your Specialty Pharmacy Service Provider to request an application, enroll or inquire about the status of an application.

    • Accredo 1-866-344-4874
    • CVS/Caremark 1-877-242-2738
    • CuraScript 1-866-474-8326

    For Adcirca®

    Contact HealthBridge (a division of ESI/CuraScript) 1-877-948-9136 to request an application, enroll or inquire about the status of an application.  

    General Info

    All applications will require:

    • Proof of income
    • Review of current health care benefits
    • A signature from the prescribing doctor to validate the diagnosis and certify the medical need

    Average notification of acceptance/denial for Patient Assistance is typically within 1-2 business days provided a complete and signed application plus required documentation has been filed with the Administrator.

    Approved applicants will receive the prescribed product for up to one year and are required to re-enroll to continue benefits. Costs associated with physician services or other medical treatments are not provided or reimbursed.

    Applications and processes should always be coordinated by the appropriate PAP Administrator listed above and below. You should not send applications directly to United Therapeutics.

    Contact Information

    Request UT PAP from the following specialty pharmacies:

    • Accredo Therapeutics 1-866-344-4874 (Remodulin® or Tyvaso®)
    • CVS/Caremark 1-877-242-2738 (Remodulin® or Tyvaso™)
    • CuraScript 1-866-47418326 (Remodulin® or Tyvaso®)
    • HealthBridge 1-877-948-9136 (Adcirca® Only)

    United Therapeutics Corporation (for information about the Patient Assistance Program only)
    1-919-485-8350

    Find out more information about Remodulin® and Tyvaso® (treprostinil)

    Find out more information about Adcirca® (tadalafil)

     

    PHA is proud to be able to make educational materials and programs like these available for free to everyone because of the generous support from members of the community just like you. Donations are welcome!

    FIND IT FAST

    Your Drug Discount Card

    Drug Discount Card

    PHA has collaborated with NeedyMeds to bring you a unique Drug Discount Card. With this card you can save up to 75% off the price of prescriptions that are not covered by insurance.

    Learn more and print your card

    The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.

    For the best viewing experience of this site, it is recommended that you use Internet Explorer 8 or 9 or Firefox.

    © 2014 Pulmonary Hypertension Association. All Rights Reserved.

    801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
    Webmaster@PHAssociation.org
        Privacy Policy   Virtual Tour of Website    Provide Feedback & Report Bugs

    Designed by Matrix Group International, Inc.®

    NORD

    The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.